Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
6-K
Operational Other
confidence 85%
filed 2026-08-28
EX-99.1
BioNTech announced termination of the Phase 2 clinical trial BNT122-01 for autogene cevumeran in colorectal cancer following a Data Safety Monitoring Board recommendation due to a numerical imbalance in overall survival and low likelihood of efficacy. This is a material operational/clinical development event affecting a key pipeline program, though it does not fit the specific categories of exec changes, M&A, impairment, or litigation. The decision reflects a significant setback in the company's oncology strategy and would affect investor assessment of pipeline prospects.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-08-27
Item 7.01
Weyerhaeuser furnished an investor presentation outlining strategic initiatives and an accelerated growth strategy targeting $1.5 billion of incremental Adjusted EBITDA by 2030, along with operational performance metrics, capital allocation framework, and sustainability goals.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-08-27
EX-99.1
This press release announces the completion of a major corporate transformation: OceanPal Inc. has changed its legal name to SVRN, Inc., divested its legacy shipping business, eliminated all debt and preferred stock, and repositioned itself as a digital asset treasury company focused on NEAR Protocol. While the name change itself is administrative, the underlying business transformation—exit from shipping, capital restructuring, and pivot to cryptocurrency/digital assets—is a material operational and strategic event that would affect a reasonable investor's assessment of the company's business model and risk profile.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-08-27
Item 8.01
The RIPUC approved a base distribution rate case for RIE (PPL's subsidiary) authorizing $44.1 million in electric and $93.7 million in gas annual revenue increases, along with a 9.275% return on equity and specified capital structure. This is a material regulatory decision affecting PPL's subsidiary's revenues and profitability, but it is primarily an operational/regulatory milestone rather than a discrete financial event (debt issuance, impairment, etc.). The filing also addresses the Hold Harmless Commitment from PPL's 2022 acquisition, with the RIPUC authorizing approximately $170 million in customer bill credits. PPL reaffirms its 2026 earnings guidance in connection with these decisions, indicating materiality to investors.
View raw filing on EDGAR →
8-K
Operational Other
confidence 85%
filed 2026-08-27
Item 8.01
VeriSign announced a price increase for .net domain registrations from $10.91 to $12.00 per ICANN agreement, effective March 1, 2027. This is a material operational and pricing decision affecting the company's core registry business revenue, but does not fit a specific named event type. The increase represents approximately 10% pricing power and would materially impact investor assessment of future revenue and margins.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-08-27
Item 7.01
The disclosure announces FDA approval of LISRAYA (brepocitinib) for dermatomyositis treatment, a significant regulatory and commercial milestone for Roivant's subsidiary Priovant. While this is a material operational event affecting the company's product portfolio and market position, it does not fit neatly into the specific event categories (e.g., it is not an earnings release, M&A activity, or material litigation). The approval represents a major product launch and regulatory achievement that would materially affect a reasonable investor's assessment of the company's pipeline and commercial prospects.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-08-27
EX-99.1
This press release announces publication of peer-reviewed clinical data demonstrating a 70% reduction in suicidal ideation among MDD patients treated with BrainsWay's Deep TMS technology. While the data supports the company's product efficacy and competitive positioning, it is a secondary analysis of previously published trial data (not a new FDA approval or regulatory milestone). The disclosure is material to investors as it strengthens the clinical evidence base for the company's lead product and supports market positioning, but it does not fit the specific event categories of earnings release, M&A, regulatory approval, or other defined types—making it an operational/strategic disclosure about product clinical validation.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-08-27
EX-99.1
The exhibit announces a 30:1 stock consolidation that commenced trading on August 27, 2026, reducing outstanding shares from 18,567,650 to 618,899. While the consolidation itself is a capital structure event, the disclosure emphasizes the Company's effort to regain compliance with Nasdaq's US$1.00 minimum bid price requirement (referenced in forward-looking statements and risk factors), indicating this is a delisting-avoidance measure. However, the exhibit does not disclose an actual delisting notice or failure to comply; it announces the consolidation as a remedial action. The event is material because it affects share structure and trading, but the primary disclosed action is the operational/structural consolidation rather than a delisting risk notice.
View raw filing on EDGAR →
8-K
Operational Other
confidence 82%
filed 2026-08-27
Item 8.01
MBX Biosciences announced the first patient dosed in its pivotal Phase 3 oPTimize trial for canvuparatide, a material clinical development milestone representing significant progress toward potential FDA registration of the company's lead product candidate.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-08-27
Item 8.01
The Trust is disclosing a material change in its NAV calculation methodology effective September 1, 2026, transitioning from the CoinDesk Ethereum Classic Price Index to the CoinDesk Ethereum Classic Benchmark Extended Rate. This operational change affects how the Trust values its ETC holdings and calculates NAV per share, which directly impacts investor valuations. While the disclosure is primarily operational/procedural in nature, the detailed explanation of the new index methodology, constituent platform selection criteria, and calculation algorithm indicates this is a significant operational event material to shareholders.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-08-27
Item 8.01
The Trust is disclosing a material change in its valuation methodology effective September 1, 2026, transitioning from the CoinDesk Horizen Reference Rate to the CoinDesk Horizen Benchmark Extended Rate for calculating NAV and NAV per Share. This operational change affects how the Trust values its ZEN holdings and directly impacts shareholder valuations, making it material to investors. The detailed description of the new Index's methodology, constituent platform selection criteria, and calculation algorithm reflects a significant operational and valuation framework change rather than a routine administrative matter.
View raw filing on EDGAR →
6-K
Operational Other
confidence 72%
filed 2026-08-27
The Company announced a delay in releasing its six- and three-month financial results for the period ended June 30, 2026, citing "ongoing impact of recently announced developments." While the filing references "previously reported" developments without detailing them, the delay itself and the forward-looking statement that the Company expects "significant operating and net losses" signal material operational or financial stress. The announcement does not fit neatly into a specific event category (not a restatement, going-concern disclosure, or covenant breach per se), but the delay in financial reporting combined with acknowledgment of material adverse developments constitutes a material operational disclosure warranting investor attention.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-08-27
EX-99.1
This press release announces POMDOCTOR's formal initiation of U.S. market entry preparations, including recruitment of U.S.-based leadership, market assessment completion, regulatory framework structuring, product localization, and exploratory partnership discussions. While the announcement describes a strategic expansion initiative rather than a discrete completed transaction, the formal commencement of U.S. market preparation—a major geographic expansion for a digital healthcare company—represents a material operational and strategic milestone that would affect a reasonable investor's assessment of the company's growth trajectory and future revenue potential. The disclosure does not fit the specific event categories (M&A, exec changes, financial results, etc.) but clearly constitutes a material operational/strategic business event.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-08-27
Item 7.01
This disclosure announces a major strategic infrastructure expansion in Pohang, Korea, including a nearly six-fold increase in electrical capacity (130 MW to 750 MW), acquisition of 1.3 million square feet of land, facility expansion from 24,000 to 482,000 square feet, and a $20.7 million Korean government grant. While this involves operational and strategic business developments (power infrastructure, land acquisition, facility expansion, production scaling), it does not fit the specific categories of M&A activity (no acquisition of another company), debt issuance, or other named financial events. The event is clearly operational and material to investors assessing the company's growth trajectory and manufacturing capacity, but is best classified as an operational/strategic milestone rather than a specific named event type.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-08-27
The filing discloses successful completion of three large-animal procedures using NeuroOne's StereoCED™ platform, demonstrating technical feasibility and a novel combination of drug delivery and electrophysiological recording. The company expects to recognize related revenue in fiscal Q4 2026 and plans to launch the platform for human investigational clinical studies later in the quarter. This represents a material operational and product development milestone for a medical device company, though it does not fit neatly into the specific operational categories (it is not a contract, partnership, or restructuring). The revenue recognition expectation and clinical launch timeline make this material to investors assessing the company's progress toward commercialization.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-08-27
Item 8.01
Faraday Future announced a multi-phase execution roadmap for its "Built in USA" robotics acceleration program, including targets to bring its robot factory online by year-end 2026 and launch first new EAI Device products in February 2027. The disclosure also covers distributor recruitment, planned $5 billion U.S. investment over ten years, and new product launches (Next Futurist and Next Aegis robots). This is a strategic operational and business development announcement that would materially affect investor assessment of the company's product roadmap, manufacturing capabilities, and market positioning, though it does not fit neatly into other specific event categories.
View raw filing on EDGAR →
8-K
Operational Other
confidence 72%
filed 2026-08-27
Item 1.01
PMGC Holdings entered into two material definitive agreements on August 27, 2026: a Trademark License Agreement with NorthStrive Companies Inc. (an entity of Chairman Braeden Lichti) granting a limited, non-exclusive license to use the NorthStrive Marks for $1.00 over five years, and an Exchange Agreement with Streeterville Capital LLC converting a Secured Pre-Paid Purchase into 80,000 shares of common stock.
View raw filing on EDGAR →
8-K
Operational Other
confidence 72%
filed 2026-08-27
Item 7.01
PMGC Holdings entered into a non-binding term sheet with Orbit2Orbit for a multi-part strategic relationship including space-based research collaboration, U.S. aerospace manufacturing services, and a CAD $200,000 equity investment, while simultaneously terminating a previously announced LOI to acquire a 76% controlling interest in an Arizona-based precision machining company following financial due diligence.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-08-27
EX-99.1
First Mining has signed a definitive Project Agreement with Cat Lake First Nation and Lac Seul First Nation covering all phases (construction, operations, closure) of the Springpole Gold Project. This is a material operational and strategic milestone that provides "certainty for the Project's development path to construction and operation" and establishes a long-term collaborative relationship with Indigenous communities. While not a discrete M&A transaction, this agreement materially advances the project's permitting and development pathway and would affect a reasonable investor's assessment of project execution risk and timeline.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-08-27
Nova Minerals disclosed achievement of a key operational milestone—shipment of ~500 tons of processing and refining equipment to its Port MacKenzie antimony plant site in Alaska. The filing emphasizes this as a significant step toward establishing a domestic antimony supply chain, with first production targeted for 2027. While the event is operational and strategic in nature (equipment procurement and logistics), it does not fit neatly into specific categories like ma_activity (no acquisition/merger), debt_issuance, or workforce_reduction. The disclosure is material to investors as it demonstrates tangible progress on a major, government-funded ($43.4M Defense Production Act award) project that is central to the company's strategy.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-08-27
Item 7.01
The disclosure centers on an operational and strategic update regarding U.S. GoldMining's 2026 exploration program at the Whistler Gold-Copper Project, including drilling progress (11 core holes, 5,000+ meters), district-scale exploration strategy, and federal policy engagement (congressional site tour on August 24, 2026). While the company references its previously announced PEA ($2.0B NPV5%), the primary focus is on ongoing exploration activities and stakeholder engagement rather than financial results or a new earnings release. This is a material operational disclosure affecting investor assessment of project development trajectory and regulatory/political support, but does not fit the specific categories of earnings_release, ma_activity, or other defined event types.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-08-27
Item 7.01
ChronoScale announced and extended its strategic partnership with Microsoft for a planned 50-megawatt AI compute deployment in North America featuring NVIDIA GB300 NVL72 systems and liquid-cooling infrastructure, with the partnership term extended from two years to three years. This material operational and strategic business event reflects significant capital deployment and operational scale-up in the AI infrastructure market.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-08-27
The filing discloses entry into a Memorandum of Understanding (Item 1.01) appointing Tru Golf Canada Inc. as an exclusive master distributor and strategic platform partner across multiple territories including Indigenous communities in Canada, Thompson Okanagan in British Columbia, Hard Rock opportunities in Oklahoma and globally, and Canadian-originated opportunities. This is a material operational and strategic partnership that grants exclusive distribution rights for TruGolf Products across defined territories with a five-year initial term, making it a significant business development event. While it could be characterized as a material contract or partnership, it does not fit the specific M&A activity definition (no acquisition, disposition, merger, or change of control), so operational_other is most appropriate.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-08-27
Item 7.01
CaliberCos announced the formation of Caliber Tokenization Services, LLC, a new business division providing real-world asset tokenization services to family offices. This is a strategic business expansion into a new service line and revenue stream. While the company reaffirms 2026 revenue projections without upward revision (suggesting limited near-term financial impact), the launch of a new fee-based service division targeting a significant market opportunity ($393 trillion in real estate assets) represents a material operational and strategic development that would affect a reasonable investor's assessment of the company's growth prospects and business model evolution.
View raw filing on EDGAR →
8-K
Operational Other
confidence 85%
filed 2026-08-27
Item 8.01
Standard Nuclear announced execution of a binding multi-year fuel supply agreement with Antares Nuclear for delivery of 1–8 MTUs of TRISO fuel through 2035. This is a material strategic commercial contract securing long-term revenue and customer relationships in the advanced nuclear sector, but does not fit the specific operational categories (workforce reduction, restructuring) or financial categories (debt, equity, M&A). The agreement represents a significant operational milestone for a fuel supplier establishing supply-chain partnerships with an advanced reactor developer.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-08-27
This disclosure announces positive Phase III trial results for Tezspire (tezepelumab) in eosinophilic esophagitis, demonstrating statistically significant efficacy across co-primary and secondary endpoints at weeks 24 and 52. While the announcement describes clinical trial success rather than a discrete financial event, M&A activity, or governance change, it represents a material operational and strategic milestone—successful Phase III data supporting potential regulatory approval and commercial expansion of a key pipeline asset into a third indication. This is material to investors assessing the company's pipeline value and growth prospects, though it does not fit neatly into the specific event categories (it is not an earnings release, which reports financial results; nor is it a restatement, impairment, or other financial accounting event). The operational domain is clear, making `operational_other` the most appropriate classification.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-08-27
Guardian Metal Resources announced publication of a Technical Report Summary for its Pilot Mountain tungsten project, prepared in accordance with S-K 1300 standards and supporting a Pre-Feasibility Study announced on 30 June 2026. This is a material operational milestone for a mineral exploration company advancing a major development project, but it does not fit the discrete event categories (not M&A, not a financial result, not an executive change, not a restatement or impairment). The disclosure is clearly operational and strategic in nature—advancing a flagship project toward development—making it material to investors assessing the company's progress and project viability.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-08-27
EX-99.1
RYET announced a three-party memorandum of understanding with the Nanchang Institute of Science and Technology and Intersect Holding to establish a Saudi-China education and technology platform supporting the company's planned "Formind" international expansion strategy. This is a material strategic partnership and institutional collaboration that advances RYET's stated objective to increase non-China revenue to over 50% by end of 2027, but it is not a discrete M&A transaction, executive change, or financial event—it is an operational/strategic business development that does not fit a more specific category.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-08-27
EX-99.1
This press release announces FDA approval of a supplemental Biologics License Application (sBLA) for an updated COVID-19 vaccine formula (COMIRNATY XFG) targeting the XFG variant for the 2026-2027 season. The approval is a regulatory milestone for an existing product line rather than a discrete financial event (earnings, debt, M&A) or governance matter. While the approval enables commercial distribution and is material to investors assessing BioNTech's vaccine business prospects, it does not fit the specific event types (e.g., earnings_release, ma_activity, exec_appointment). This is best classified as an operational/strategic milestone—a material product approval and launch announcement.
View raw filing on EDGAR →
8-K
Operational Other
confidence 72%
filed 2026-08-27
Item 8.01
The filing discloses a material operational and strategic update: the company has resumed SOL (Solana) purchases, acquiring approximately 19,000 SOL and expanding its treasury to 2.33M SOL equivalents. This represents a significant capital deployment decision and treasury management action central to the company's stated strategy of accumulating and compounding Solana holdings. While not a traditional M&A transaction, debt issuance, or earnings release, this treasury expansion and asset acquisition strategy is material to investors assessing the company's execution of its core business model and capital allocation priorities.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-08-26
EX-99.1
Nicola Mining has entered into a Mining and Milling Profit Share Agreement with Red Eye Resources, permitting Red Eye to transport mineralized material to Nicola's Merritt Mill for processing with equal profit sharing. This is a material operational and strategic partnership that leverages Nicola's unique milling infrastructure and permitting position to generate near-term economic value, as emphasized by CEO Peter Espig's commentary on the company's strategy to use the mill as a "centralized processing platform." While not a traditional M&A transaction, this agreement materially expands the company's revenue-generating opportunities and business model.
View raw filing on EDGAR →
8-K
Operational Other
confidence 85%
filed 2026-08-26
Item 8.01
Target Hospitality announced a new multi-year lease and services agreement with a top-five hyperscaler to provide facility and hospitality services for a data center development in West Texas, expected to generate approximately $250 million in revenue through August 2030. The company simultaneously raised its full-year 2026 revenue and Adjusted EBITDA outlook by 6% and 22% respectively, reflecting the material impact of this strategic contract win on the company's Workforce Hospitality Solutions segment.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-08-26
EX-99.1
The press release announces finalization of a C$17.5M funding agreement with Invest Ontario for construction of Electra's cobalt sulfate refinery, along with a long-term cobalt supply agreement with Glencore (10,000 tonnes over five years). These are material operational and strategic milestones—securing government funding, establishing feedstock supply, and advancing toward commercial production in Q4 2027—that would affect a reasonable investor's assessment of the company's ability to execute its core business plan. The disclosure also mentions issuance of 500,000 incentive stock options to employees, which is a minor governance/compensation element but secondary to the primary operational announcements.
View raw filing on EDGAR →
8-K
Operational Other
confidence 85%
filed 2026-08-26
Item 8.01
Celcuity announced submission of a supplemental New Drug Application (sNDA) to the FDA for REVTORPYK (gedatolisib) for HR+/HER2- breast cancer with PIK3CA mutations, representing a material regulatory milestone and significant step toward expanding the approved indication for the already-approved drug based on positive Phase 3 VIKTORIA-1 trial results.
View raw filing on EDGAR →
8-K
Operational Other
confidence 85%
filed 2026-08-26
Item 8.01
The disclosure announces FDA approval of RASONQUE (daraxonrasib) for metastatic pancreatic adenocarcinoma, a major regulatory and commercial milestone for Revolution Medicines. This is a material operational event—the product is now available for prescription in the United States—but does not fit the specific named categories (earnings, M&A, impairment, etc.). The approval is based on successful Phase 3 trial data (RASolute 302) and includes pricing information ($39,800 for a 30-day supply), indicating commercial readiness and materiality to investors assessing the company's pipeline and revenue prospects.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-08-26
Item 7.01
Ovintiv disclosed a material update on its 2026 "ground game acquisition program," announcing over 60 transactions adding approximately 41,000 net acres and 240 well locations across Permian and Montney assets for ~$460 million. While this involves acquisitions of land and drilling inventory, the disclosure focuses on an operational/strategic capital deployment program rather than a discrete M&A transaction meeting the definition of "material acquisition" (Item 1.01). The company characterizes this as an ongoing inventory-building initiative with multiple small transactions, making it an operational capital strategy rather than a single material M&A event.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-08-26
Item 8.01
Gulf Resources announced a strategic cooperation agreement with Brazilian company Montes Verdes Participacoes Ltda. to establish a joint venture for international expansion in bromine, lithium, and other mineral extraction. The agreement includes revenue guarantees ($180M in 2027, 20% annual growth thereafter) and potential dilutive share issuance. This is a material operational and strategic business event involving a partnership and joint venture formation, but does not constitute a traditional M&A transaction (acquisition, merger, or change of control). The disclosure is material to investors as it represents a significant strategic pivot and expansion plan with financial commitments and potential equity dilution.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-08-26
EX-99.1
This announcement discloses a material clinical milestone: dosing the first patient in the second cohort of a Phase 1/2a trial of RV-01, the company's lead radiopharmaceutical therapeutic developed through its joint venture with MD Anderson Cancer Center. The advancement to the 70 mCi dose level following a positive Safety and Monitoring Committee recommendation represents a significant operational and clinical progression for a clinical-stage biopharmaceutical company. While not a discrete event type like M&A, exec change, or debt issuance, this clinical advancement is material to investors' assessment of the company's pipeline development and is best classified as an operational milestone.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-08-26
EX-99.1
This press release announces record operational metrics for H1 2026: customer count reached 550 (up 17.8% YoY), project backlog hit record levels, and IPO filing submissions surged 482% to 64 times. While the release explicitly states it "contains operating information only and does not contain financial results," the magnitude of growth in customer acquisition (37.2% YoY from 2024) and the dramatic 482% increase in IPO submissions represent material operational developments that would affect a reasonable investor's assessment of the company's business trajectory and capacity to monetize demand.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-08-26
EX-99.1
This is a monthly operations and production update disclosing material operational milestones: a $4.7B, 16-year AI/HPC data center lease for Tydal, Norway; full commitment of the 9.5MW A102 facility in Malaysia with over $800M in expected contracted revenue; and 322% year-over-year increase in Bitcoin production to 1,190 BTC. While the document contains operational metrics and updates rather than discrete event announcements (like M&A completion or executive changes), the scale of the Norway lease commitment and the AI Cloud facility's full capacity commitment represent material operational developments affecting the registrant's revenue trajectory and strategic positioning.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-08-26
EX-99.1
This press release announces a binding customised structural development contract entered into on August 22, 2026, between Mint's subsidiary AXONEX, Beijing Yunji Technology, and Rice Robotics to co-develop a next-generation commercial-grade service robot. The disclosure describes a strategic partnership with planned production of approximately 1,000 units annually and projected revenue of HK$50–100 million, representing a material operational and strategic business development. While this is a partnership/contract rather than a discrete M&A transaction, it constitutes a material operational milestone involving significant commercial commitment and market expansion across Asia.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-08-26
Item 1.01
Ark 21Shares Bitcoin ETF entered into a Benchmark Licensing Agreement with FTSE to replace the terminated CME CF Bitcoin Reference Rate as the pricing benchmark for the ETF's net asset value calculation, effective August 27, 2026, and amended its Sponsor Agreement to change sponsor fee payment timing from weekly to quarterly in arrears. These operational changes are material to investors as the benchmark change directly affects how the ETF's shares are valued and priced.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-08-26
Item 1.01
21Shares entered into two material definitive agreements: (1) a Benchmark Licensing Agreement with FTSE to replace the CME CF Ether-Dollar Reference Rate as the pricing benchmark for the ETF's net asset value calculation, effective August 27, 2026, and (2) Amendment No. 2 to the Sponsor Agreement changing sponsor fee payment timing from weekly to quarterly in arrears. These contractual arrangements are material to the ETF's ongoing administration and valuation methodology.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-08-26
Item 1.01
The Trust entered into a Benchmark Licensing Agreement with FTSE to replace the CME CF Solana-Dollar Reference Rate as the pricing benchmark for NAV calculation, effective August 27, 2026, and amended the Sponsor Agreement to change sponsor fee payment timing from weekly to quarterly in arrears.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-08-26
Item 1.01
The Trust entered into two material definitive agreements: a Benchmark Licensing Agreement with FTSE to replace the CME CF Polkadot-Dollar Reference Rate as the pricing benchmark for NAV calculation effective August 27, 2026, and Amendment No. 1 to the Sponsor Agreement changing sponsor fee payment timing from weekly to quarterly arrears.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-08-26
Item 1.01
Treasure Global Inc entered into three Software Development Agreements totaling US$3,000,000 to design and develop a Lifestyle Membership and Experience Platform, representing a material strategic operational commitment.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-08-26
Item 1.01
21Shares Dogecoin ETF entered into a Benchmark Licensing Agreement with FTSE to replace the terminated CF Benchmarks licensing agreement, effective August 27, 2026, which directly impacts NAV calculation methodology. Additionally, Amendment No. 1 to the Sponsor Agreement changed sponsor fee payment timing from weekly to quarterly.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-08-26
Item 1.01
21Shares entered into a Benchmark Licensing Agreement with FTSE to replace the CME CF Sui-Dollar Reference Rate as the pricing benchmark for the ETF's net asset value calculation, effective August 27, 2026, and amended its Sponsor Agreement to change sponsor fee payment timing from weekly to quarterly arrears. These material operational agreements govern the ETF's core pricing and fee mechanics.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-08-26
Item 1.01
21Shares XRP ETF entered into a Benchmark Licensing Agreement with FTSE to replace the terminated CME CF XRP-Dollar Reference Rate as the pricing benchmark for the Trust's NAV calculation, effective August 27, 2026, and amended its Sponsor Agreement to change sponsor fee payment timing from weekly to quarterly in arrears. These changes are material to investors as they affect NAV calculation methodology and fee payment terms.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-08-26
EX-99.1
This news release announces two material operational milestones: (1) signing of Administrative Mining Contracts (AMCs) for the Carangas Project covering 39 km² with a 30-year fixed term, representing conversion from exploration to a long-term mining framework and de-risking the permitting pathway; and (2) commencement of a 30,000-metre 2026 drill program scheduled for September 8, 2026. These are significant project advancement events that would affect a reasonable investor's assessment of the company's development progress and de-risking trajectory, but they do not fit the specific event-type categories (not M&A, not a discrete financial event, not governance, not litigation). The operational nature and materiality to project advancement support classification as operational_other.
View raw filing on EDGAR →